文献速递乳房整形与再造

DermACELL与Braxon在胸肌前植入物乳房重建中的并发症比较

Comparison of DermACELL™ and Braxon® in prepectoral implant-based breast reconstruction: Complication rates and clinical implications.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2026-08-14

本研究回顾性比较了125例胸肌前植入物乳房重建病例,其中Braxon组58例、DermACELL组67例。总体并发症发生率为37.6%,血清肿(14.4%)和伤口裂开(13.6%)最常见。两组在并发症发生率或发生时间上无显著差异,Braxon组再手术率数值上更高但未达统计学显著性(p=0.063)。

要点

  • 胸肌前植入物乳房重建中,Braxon与DermACELL两组总体并发症率无显著差异。
  • 最常见并发症为血清肿(14.4%)和伤口裂开(13.6%)。
  • Braxon组再手术率数值上高于DermACELL组,但差异未达统计学显著(p=0.063)。

核心结论

  • 在胸肌前植入物乳房重建中,Braxon与DermACELL在总体并发症、主要并发症或特定并发症上无统计学显著差异。

研究设计与样本

  • 单中心回顾性研究,纳入2022年6月至2026年1月期间接受胸肌前植入物乳房重建并使用Braxon或DermACELL的患者,共125例(Braxon组58例,DermACELL组67例)。
  • 采用单变量分析比较组间差异,并使用多变量逻辑回归校正混杂因素。

主要发现

  • 总体并发症发生率为37.6%(n=47),其中轻微并发症18.4%,主要并发症19.2%。
  • 最常见并发症为血清肿(14.4%)和伤口裂开(13.6%)。
  • 包膜挛缩≥III级发生率为7.2%,再手术率为18.4%。
  • 两组在并发症发生率或发生时间上无显著差异;Braxon组再手术率数值上高于DermACELL组,但未达统计学显著性(p=0.063)。

临床怎么用

  • 选择Braxon或DermACELL时,两者并发症谱未见显著差异,决策可综合考虑机构习惯、术者偏好及围手术期方案。
  • 需关注血清肿和伤口裂开等常见并发症的预防与监测。

局限性

  • 单中心回顾性设计。
  • 样本量有限(共125例)。
  • 两组在抗生素方案和术者分布上存在差异。
  • 需要更大规模的前瞻性研究评估长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer remains the most common malignancy among women worldwide, with many patients undergoing mastectomy followed by implant-based reconstruction (IBR). Prepectoral IBR has gained popularity due to reduced postoperative pain and improved esthetic outcomes. This approach frequently utilizes acellular dermal matrices (ADMs), including DermACELL™ (human-derived, partial coverage) and Braxon® (porcine-derived, full-wrap), which differ in composition and surgical application. Evidence comparing their complication profiles remains inconclusive. This study aimed to compare postoperative outcomes between these two ADMs in prepectoral IBR. METHODS: A retrospective review was conducted of patients who underwent prepectoral IBR with Braxon® or DermACELL™ between June 2022 and January 2026 at a single institution. Data collected included demographics, surgical characteristics, ADM type, adjuvant therapy, and postoperative complications. Groups were compared using univariable analyzes, and multivariable logistic regression was performed to adjust for confounders. RESULTS: A total of 125 cases were included (58 Braxon®, 67 DermACELL™). Baseline demographics and operative characteristics were comparable. Differences were noted in antibiotic regimens and surgeon distribution. The overall complication rate was 37.6% (n=47), including 18.4% minor and 19.2% major complications. The most common complications were seroma (14.4%) and wound dehiscence (13.6%). Capsular contracture ≥ grade III occurred in 7.2%, and reoperation was required in 18.4% of cases. No significant differences were observed between groups in complication rates or timing. Reoperation was numerically higher in the Braxon® group than in the DermACELL™ group, although this did not reach statistical significance (p = 0.063). CONCLUSION: No statistically significant differences in overall complications, major complications, or specific complications were observed between Braxon® and DermACELL™ in prepectoral IBR. Observed differences may reflect institutional practices, surgeon preference, or perioperative protocols rather than ADM-specific effects alone. Larger prospective studies are needed to evaluate long-term outcomes.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Kotovich D, Rittblat M, Blum A, et al. Comparison of DermACELL™ and Braxon® in prepectoral implant-based breast reconstruction: Complication rates and clinical implications. J Plast Reconstr Aesthet Surg. 2026. PMID: 42612275. doi:10.1016/j.bjps.2026.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。